



Article professionnel

Article

2013

Published version

Open Access

This is the published version of the publication, made available in accordance with the publisher's policy.

---

Effect of intraoperative high inspired oxygen fraction on surgical site infection, postoperative nausea and vomiting, and pulmonary function: systematic review and meta-analysis of randomized controlled trials

---

Hovaguimian, Frederique; Lysakowski, Christopher; Elia, Nadia; Tramer, Martin

#### How to cite

HOVAGUIMIAN, Frederique et al. Effect of intraoperative high inspired oxygen fraction on surgical site infection, postoperative nausea and vomiting, and pulmonary function: systematic review and meta-analysis of randomized controlled trials. In: *Anesthesiology*, 2013, vol. 119, n° 2, p. 303–316. doi: 10.1097/ALN.0b013e31829aaff4

This publication URL: <https://archive-ouverte.unige.ch/unige:32864>

Publication DOI: [10.1097/ALN.0b013e31829aaff4](https://doi.org/10.1097/ALN.0b013e31829aaff4)

# Effect of Intraoperative High Inspired Oxygen Fraction on Surgical Site Infection, Postoperative Nausea and Vomiting, and Pulmonary Function

## Systematic Review and Meta-analysis of Randomized Controlled Trials

Frédérique Hovaguimian, M.D.,\* Christopher Lysakowski, M.D.,† Nadia Elia, M.D., M.Sc.,‡ Martin R. Tramèr, M.D., D.Phil.§



This article has been selected for the ANESTHESIOLOGY CME Program. Learning objectives and disclosure and ordering information can be found in the CME section at the front of this issue.

### ABSTRACT

**Background:** Intraoperative high inspired oxygen fraction ( $F_{IO_2}$ ) is thought to reduce the incidence of surgical site infection (SSI) and postoperative nausea and vomiting, and to promote postoperative atelectasis.

**Methods:** The authors searched for randomized trials (till September 2012) comparing intraoperative high with normal  $F_{IO_2}$  in adults undergoing surgery with general anesthesia and reporting on SSI, nausea or vomiting, or pulmonary outcomes.

**Results:** The authors included 22 trials (7,001 patients) published in 26 reports. High  $F_{IO_2}$  ranged from 80 to 100% (median, 80%); normal  $F_{IO_2}$  ranged from 30 to 40% (median, 30%). In nine trials (5,103 patients, most received prophylactic antibiotics), the incidence of SSI decreased from 14.1% with normal  $F_{IO_2}$  to 11.4% with high  $F_{IO_2}$ ; risk ratio, 0.77 (95% CI, 0.59–1.00). After colorectal surgery, the incidence of SSI decreased from 19.3 to 15.2%; risk ratio, 0.78 (95% CI, 0.60–1.02). In 11 trials (2,293 patients), the

### What We Already Know about This Topic

- There have been conflicting findings regarding the role of high inspired oxygen fraction and perioperative outcomes

### What This Article Tells Us That Is New

- Intraoperative high inspired oxygen fraction decreases the risk of surgical site infection in surgical patients receiving prophylactic antibiotics, has a weak beneficial effect on nausea, and does not increase the risk of postoperative atelectasis

incidence of nausea decreased from 24.8% with normal  $F_{IO_2}$  to 19.5% with high  $F_{IO_2}$ ; risk ratio, 0.79 (95% CI, 0.66–0.93). In patients receiving inhalational anesthetics without prophylactic antiemetics, high  $F_{IO_2}$  provided a significant protective effect against both nausea and vomiting. Nine trials (3,698 patients) reported on pulmonary outcomes. The risk of atelectasis was not increased with high  $F_{IO_2}$ .

**Conclusions:** Intraoperative high  $F_{IO_2}$  further decreases the risk of SSI in surgical patients receiving prophylactic antibiotics, has a weak beneficial effect on nausea, and does not increase the risk of postoperative atelectasis.

IT has been claimed that patients undergoing surgery with general anesthesia were benefiting from a higher than normal inspired oxygen fraction ( $F_{IO_2}$ ).<sup>1,2</sup> Some authors have suggested that a high  $F_{IO_2}$  was a simple, inexpensive, and low-risk intervention, and that the broader use of this technique should be encouraged in patients undergoing major abdominal procedures.<sup>3</sup> Randomized trials have reported on a reduced risk of surgical site infection (SSI) in patients who were ventilated with 80%  $F_{IO_2}$  during surgery.<sup>4,5</sup> It was also shown that patients who were ventilated with high  $F_{IO_2}$  intraoperatively had a reduced incidence of postoperative nausea and vomiting (PONV).<sup>6,7</sup>


Other authors were more cautious.<sup>8,9</sup> Skepticism has been partly related to the fact that high  $F_{IO_2}$  may have deleterious

\* Registrar, † Consultant, Division of Anesthesiology, Geneva University Hospitals, Geneva, Switzerland. ‡ Research Associate, Division of Anesthesiology, Geneva University Hospitals, and Institute of Social and Preventive Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland. § Professor, Division of Anesthesiology, Geneva University Hospitals, and Faculty of Medicine, University of Geneva.

Received from the Division of Anesthesiology, Department of Anesthesiology, Clinical Pharmacology, and Critical Care, Geneva University Hospitals, Geneva, Switzerland. Submitted for publication July 9, 2012. Accepted for publication March 14, 2013. Support was provided solely from institutional and/or departmental sources. Presented at the Euroanaesthesia Meeting, June 9–12, 2012, Paris, France. Supplementary material is freely accessible on the author's Web site at <http://www.hcuge.ch/anesthesie/data.htm>.

Address correspondence to Dr. Hovaguimian: Division of Anesthesiology, University Hospital of Zürich, Zürich, Switzerland. [frederique.hovaguimian@usz.ch](mailto:frederique.hovaguimian@usz.ch). This article may be accessed for personal use at no charge through the Journal Web site, [www.anesthesiology.org](http://www.anesthesiology.org).

Copyright © 2013, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins. Anesthesiology 2013; 119:303-16



**Fig. 1.** Study selection. §Four reports were subgroup analyses. \*Numbers do not add up because some reports reported on two endpoints.  $\text{FiO}_2$  = inspired oxygen fraction; High =  $\text{FiO}_2 \geq 50\%$ ; normal =  $\text{FiO}_2 < 50\%$ ;  $\text{O}_2$  = oxygen; PONV = postoperative nausea and vomiting; RCT = randomized controlled trial.

effects on the airways. One hundred percent oxygen at induction or at the end of general anesthesia has been suggested

to promote atelectasis over a few minutes,<sup>10–12</sup> and to cause alteration in gas exchange.<sup>13</sup>

**Table 1.** Characteristics of Included Randomized Controlled Trials Reporting on Surgical Site Infection

First Author	Comparison (N° Analyzed)	Surgery	Carrier Gas	Epidural Analgesia	Fluid Regimen
Greif <sup>5</sup>	1. $\text{FiO}_2$ 30% (250) 2. $\text{FiO}_2$ 80% (250)	Colorectal	Air*	No data	Aggressive
Pryor <sup>66</sup>	1. $\text{FiO}_2$ 35% (80) 2. $\text{FiO}_2$ 80% (80)	Major abdominal	$\text{N}_2\text{O}$	No data	Aggressive
Belda <sup>4</sup>	1. $\text{FiO}_2$ 30% (143) 2. $\text{FiO}_2$ 80% (148)	Colorectal	Air	No data	Aggressive
Mayzler <sup>62</sup>	1. $\text{FiO}_2$ 30% (19) 2. $\text{FiO}_2$ 80% (19)	Colorectal	Air/ $\text{N}_2\text{O}$	No data	Aggressive
Myles <sup>64</sup>	1. $\text{FiO}_2$ 30% (1,015) 2. $\text{FiO}_2$ 80% (997)	Any >2 h; excluding cardiac or one-lung ventilation	Air/ $\text{N}_2\text{O}$	100%	Not standardized
Meyhoff <sup>63</sup>	1. $\text{FiO}_2$ 30% (701) 2. $\text{FiO}_2$ 80% (685)	Abdominal	Air	70%	Restrictive
Bickel <sup>58</sup>	1. $\text{FiO}_2$ 30% (103) 2. $\text{FiO}_2$ 80% (107)	Appendectomy	Air/ $\text{N}_2\text{O}$	No data	Aggressive
Schietroma <sup>28</sup>	1. $\text{FiO}_2$ 30% (37) 2. $\text{FiO}_2$ 80% (35)	Colorectal	Air	No data	Aggressive
Thibon <sup>30</sup>	1. $\text{FiO}_2$ 30% (208) 2. $\text{FiO}_2$ 80% (226)	Abdominal, gynecologic, breast	Air	No data	No data

Quality assessment: R (randomization): 0 = none or pseudo-randomization, 1 = yes but not specified, 2 = yes and adequate; C (concealment of treatment allocation): 0 = none, 1 = yes; B (blinding): 0 = none, 1 = yes but not specified, 2 = yes and adequate; F (follow-up): 0 = none, 1 = reported but intention-to-treat analysis not possible, 2 = reported and intention-to-treat analysis possible. Trials are listed in alphabetical order.

\* Nitrogen. † Standardized 3-point scoring method. ‡ Standardized 4-point scoring method.

ASEPSIS = scoring system for wound infection; CDC = Centers for Disease Control and Prevention Scoring System for wound infection;  $\text{FiO}_2$  = inspired oxygen fraction;  $\text{N}_2\text{O}$  = nitrous oxide.

Both SSI and PONV remain a crucial topic for anesthesiologists and surgeons, as they represent a significant clinical and economic burden; SSI may lead to prolonged length of stay and increased hospital costs,<sup>14-16</sup> whereas PONV symptoms are among the most frequent adverse effects of anesthesia and surgery, and they are also associated with incremental costs.<sup>17-19</sup> Meta-analyses of clinical trials addressing the potential benefit of high F<sub>IO<sub>2</sub></sub> in surgical patients have reported conflicting results.<sup>20-26</sup> A number of further relevant clinical trials studying these issues have been published recently.<sup>27-30</sup> The aim of our study was to update previously published meta-analyses, and to provide a comprehensive quantitative summary of the most important, potentially beneficial (decrease in the risk of SSI or PONV) and harmful (increase in the risk of pulmonary complications) effects of intraoperative high inspired F<sub>IO<sub>2</sub></sub> on surgical patients.

**Materials and Methods**

We followed the PRISMA guidelines for reporting the meta-analyses of randomized controlled trials.<sup>31</sup>

**Eligibility Criteria**

We searched for fully published reports of randomized comparisons of intraoperative high F<sub>IO<sub>2</sub></sub> (experimental intervention) versus normal (*i.e.*, “low”) F<sub>IO<sub>2</sub></sub> (control intervention).

A high F<sub>IO<sub>2</sub></sub> was defined as an F<sub>IO<sub>2</sub></sub> of 50% or more, and a normal F<sub>IO<sub>2</sub></sub> as an F<sub>IO<sub>2</sub></sub> of less than 50%.

In trials with a limited high-to-normal F<sub>IO<sub>2</sub></sub> ratio, the difference in oxygen regimens may be too small and consequently the high F<sub>IO<sub>2</sub></sub> regimen may not have the scope to show efficacy. In addition, such trials may produce positive results by random chance. Consequently, there was an arbitrary *pre hoc* decision to include only studies where the normal F<sub>IO<sub>2</sub></sub> value was less than, or equal to, half of the high F<sub>IO<sub>2</sub></sub> value.

We considered studies that were performed in adult patients (≥18 yr) undergoing any surgical procedure with general anesthesia and that reported on at least one of the three outcomes: (1) SSI; (2) PONV; (3) intra- or postoperative pulmonary outcomes.

Data from animal studies or abstracts were not considered. Reports of patients undergoing surgery with regional anesthesia, patients undergoing one-lung surgery, or patients receiving high F<sub>IO<sub>2</sub></sub> in other settings than general anesthesia for surgery as, for instance, patients ventilated in the intensive care or in the prehospital setting, were excluded. Studies where supplemental oxygen was administered only postoperatively, or for a restricted time during anesthesia (for instance, at induction or during a short period before extubation), were not considered.

**Table 1.** (Continued)

Temperature Goal	Prophylactic Antibiotics, %	Additional Characteristics				Quality Assessment			
		Blood Transfusion, %	Perioperative Tissue O <sub>2</sub> Measure	Pain Control	Definition of Infection	R	C	B	F
Yes	100	30	Yes	Not standardized	ASEPSIS	2	1	2	2
No	99	4	No	Not standardized	Standardized†	2	1	2	2
Yes	100	15	No	Standardized	ASEPSIS	2	1	2	2
Yes	100	0	No	Standardized	Not standardized	2	0	1	1
Yes	90	No data	No	Not standardized	Not standardized	2	0	2	2
Yes	94	18	No	No data	CDC	2	1	2	2
Yes	100	0	No	Not standardized	ASEPSIS	1	1	2	0
Yes	100	No data	No	Standardized	Standardized‡	1	0	1	0
Yes	52	2	No	No data	CDC	2	0	2	2

### Information Sources

We performed a variety of high-sensitivity and low-specificity searches for relevant reports in the MEDLINE, Embase, and Central Databases. Key words (“oxygen,” “supplemental,” and “anesthesia”) were combined using the Boolean meanings of “and” and “or.” The last electronic search was done in September 2012. Bibliographies of retrieved articles were searched for additional references. We applied no restriction on language.

### Study Selection

Retrieved articles were reviewed for inclusion by one author (Dr. Hovaguimian), and criteria for inclusion were independently checked by another author (Dr. Lysakowski). Queries were resolved through discussion with a third author (Dr. Tramèr).

### Risk of Biases in Individual Studies

Quality of data reporting was assessed by one author (Dr. Hovaguimian) and was independently checked by another (Dr. Lysakowski), using a modified 4-items, 7-points Oxford scale taking into account method of randomization, concealment of treatment allocation, degree of blinding, and reporting of drop-outs, as previously described.<sup>32</sup> Consensus was reached by discussion with a third author (Dr. Tramèr).

Because potential confounding factors (for instance, carrier gas or fluid regimen) may directly affect the occurrence of SSI, regardless of the  $\text{FiO}_2$ ,<sup>1,33,34</sup> we retrieved such information from each study. For the analysis of SSI data, nitrous oxide was not regarded as a potential confounding factor.<sup>35</sup> However, for the analyses of PONV data, we excluded data from studies that used nitrous oxide as a carrier gas, because nitrous oxide has emetogenic properties.<sup>36</sup>

### Data Extraction Process

One author (Dr. Hovaguimian) extracted all relevant information from original reports. Another author (Dr. Lysakowski) independently checked all extracted data. Discrepancies were resolved by discussion with a third author (Dr. Tramèr).

### Data Items

Definitions of SSI were taken as reported in the original reports. Three distinct PONV outcomes were analyzed:<sup>37</sup> nausea, vomiting (including retching), and a composite endpoint (*i.e.*, nausea and/or vomiting/retching). Cumulative incidences of these outcomes were extracted for two time periods, an early period (0–6h), and a late period (0–24h).

† Ochmann C, Tuschy B, Beschmann R, Hamm F, Rohm KD, Piper SN: Supplemental oxygen reduces serotonin levels in plasma and platelets during colorectal surgery and reduces postoperative nausea and vomiting. *Eur J Anaesthesiol* 2010; 27:1036–43.

# Fujii Y, Itakura M: Supplemental intraoperative oxygen prevents postoperative nausea and vomiting in patients undergoing gynecological laparoscopic surgery. *Anesth Resusc* 2008; 44:47–50.

Pulmonary complications were defined as any adverse event occurring intra- or postoperatively and affecting the lower respiratory tract and/or interfering with normal test values related to lung integrity (blood gases, spirometry, chest imagery, arterial oxygen saturation measure by pulse oximetry, and postoperative oxygen requirements).

### Synthesis of Results

For dichotomous data, we calculated risk ratios (RR) with 95% CI. When the 95% CI around the RR point estimate did not include 1, the difference between experimental and control group was considered statistically significant.

For continuous data, weighted mean differences with 95% CI were calculated. We performed formal heterogeneity testing. When the data were homogenous ( $P \geq 0.1$ ), we used a fixed effect model to combine data from independent trials. When the data were heterogeneous, we searched for sources of heterogeneity. For example, if one study showed results that were completely out of range of the others, we searched for likely reasons explaining the difference and performed a sensitivity analysis excluding that study, when deemed appropriate. When no source could be identified that explained the heterogeneity, we combined the data using a random effects model. Sources of heterogeneity to be sought were not prespecified.

Analyses were performed using STATA 11 (Version 11; StataCorp, College Station, TX), RevMan (Computer Program, version 5.1.6; The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark), and Microsoft Excel® 12.2.3. for Mac (Microsoft Corporation, Redmond, WA).

## Results

### Study Selection

We retrieved 204 articles (fig. 1). Of 45 potentially relevant randomized trials, 19 were excluded after more thorough examination. In four, the  $\text{FiO}_2$  in control patients was more than 50%.<sup>38–41</sup> Data from six studies could not be extracted for meta-analysis: four reported measures of associations<sup>42–45</sup> and two provided results in graphical format only.<sup>46,47</sup> Three included data from children.<sup>48–50</sup> In three trials, the oxygen fraction administered in the control group was more than half of that administered in the experimental group; two of those compared 50 with 30%,<sup>51,52</sup> and one compared 60 with 45%.<sup>53</sup> One trial was using nitrous oxide as a carrier gas and reported on PONV outcomes only.<sup>54</sup> Finally, two studies were recently retracted due to ethical concerns.†#

We eventually included data from 22 randomized trials (7,001 patients) that were reported in 26 articles.<sup>4–7,27–30,55–72</sup> Seven reports with additional data from 900 patients have not been considered for any previously published meta-analyses.<sup>27–30,61,69,70</sup> Two articles reporting on pulmonary outcomes<sup>56</sup> and PONV,<sup>7</sup> respectively, were subgroup analyses of a multicenter study that reported on SSI.<sup>5</sup> Results of

**Table 2.** Characteristics of Included Randomized Controlled Trials Reporting on Postoperative Nausea and Vomiting

First Author	Comparison (N° Analyzed) (Data Not Considered)	Carrier Gas	Surgery	Additional Characteristics				Quality Assessment			
				Prophylactic Antiemetics	Anesthesia Technique	Intraoperative Analgesia	Postoperative Analgesia	R	C	B	F
Bhatnagar <sup>57</sup>	1. FiO <sub>2</sub> 30% (20) 2. FiO <sub>2</sub> 50% (20) 3. FiO <sub>2</sub> 80% (20)	Air	Breast	No	Inhalational (isoflurane)	Meperidine	Not standardized	2	0	0	0
Goll <sup>6</sup>	1. FiO <sub>2</sub> 30% (80) 2. FiO <sub>2</sub> 80% (79) [3. FiO <sub>2</sub> 30% + ondansetron (81)]	Air*	Gynecological laparoscopy	No	Inhalational (isoflurane)	Fentanyl	Not standardized (piritramid)	2	1	2	0
Greif <sup>7</sup>	1. FiO <sub>2</sub> 30% (119) 2. FiO <sub>2</sub> 80% (112)	Air*	Colorectal	No	Inhalational (isoflurane)	Sufentanil	Paracetamol Tramadol	2	1	2	0
Joris <sup>59</sup>	1. FiO <sub>2</sub> 30% (50) 2. FiO <sub>2</sub> 80% (50) [3. FiO <sub>2</sub> 30% + droperidol (50)]	Not specified	Thyroid	No	Inhalational (sevo-flurane)	Fentanyl Ketorolac	Paracetamol Codeine Morphine	1	0	2	0
McKeen <sup>27</sup>	1. FiO <sub>2</sub> 30% (145) 2. FiO <sub>2</sub> 80% (147)	Air*	Gynecological laparoscopy	No	Inhalational (desflurane)	Fentanyl	Piritramid Diclofenac	2	1	2	2
Piper <sup>65</sup>	1. FiO <sub>2</sub> 40% (125) 2. FiO <sub>2</sub> 80% (125) 3. FiO <sub>2</sub> 40% (131)	Air	Laparoscopic cholecystectomy	Dolasetron	Inhalational (desflurane)	Fentanyl	Paracetamol Oxycodone	1	1	1	2
Purhonen <sup>68</sup>	1. FiO <sub>2</sub> 30% (50) 2. FiO <sub>2</sub> 80% (49)	Air*	Gynecological laparoscopy	No	Inhalational (sevo-flurane)	Fentanyl Ketorolac	Paracetamol Ibuprofen	2	0	2	1
Purhonen <sup>67</sup>	1. FiO <sub>2</sub> 30% (28) 2. FiO <sub>2</sub> 80% (29) [3. FiO <sub>2</sub> 30% + ondansetron (28)]	Air*	Breast	No	Inhalational (sevo-flurane)	Fentanyl	Diclofenac Fentanyl Meperidine	2	0	2	2
Šimurina <sup>29</sup>	1. FiO <sub>2</sub> 30% (36) 2. FiO <sub>2</sub> 80% (36) [3. FiO <sub>2</sub> 50% (36)]	Air	Gynecological laparoscopy	No	Inhalational (sevo-flurane)	Not standardized	Not standardized	2	0	2	2
Thibon <sup>30</sup>	1. FiO <sub>2</sub> 30% (208) 2. FiO <sub>2</sub> 80% (226)	Not specified	Abdominal, gynecologic, and breast	No	Mixed (inhalational, intravenous, or both)	Fentanyl Remifentanyl NSAIDs Morphine	Not standardized	2	0	2	2
Turan <sup>71</sup>	1. FiO <sub>2</sub> 30% (279) 2. FiO <sub>2</sub> 80% (280)	Air*	Any	Ondansetron Dexamethason Droperidol	Mixed (inhalational or intravenous)	Meperidine	Not standardized	2	2	1	1

Quality assessment: R (randomization): 0 = none or pseudo-randomization, 1 = yes but not specified, 2 = yes and adequate; C (concealment of treatment allocation): 0 = none, 1 = yes; B (blinding): 0 = none, 1 = yes but not specified, 2 = yes and adequate; F (follow-up): 0 = none, 1 = reported but intention-to-treat analysis not possible, 2 = reported and intention-to-treat analysis possible. Trials are listed in alphabetical order.

\* Nitrogen.

FiO<sub>2</sub> = inspired oxygen fraction; NSAIDs = nonsteroidal antiinflammatory drugs.

**Table 3.** Characteristics of Included Randomized Controlled Trials Reporting on Pulmonary Outcomes

First Author	Comparison (N° Analyzed) (Data Not Considered)	Surgery	Additional Characteristics				Quality Assessment			
			Epidural Analgesia	Mean BMI >30kg/m <sup>2</sup>	Standardized Ventilation	PEEP, mmHg	R	C	B	F
Agarwal <sup>55</sup>	1. FiO <sub>2</sub> 40% (9) 2. FiO <sub>2</sub> 100% (9) [3. FiO <sub>2</sub> 40% + N <sub>2</sub> O (9)]	Laparoscopic cholecystectomy	No data	No	VC, TV 8 ml/kg ETco <sub>2</sub> 35–40 mmHg	No data	2	0	0	1
Akça <sup>56</sup>	1. FiO <sub>2</sub> 30% (14) 2. FiO <sub>2</sub> 80% (16)	Colorectal	No data	No	VC, TV 10 ml/kg ETco <sub>2</sub> 35 mmHg	0	2	1	2	0
Kotani <sup>60</sup>	1. FiO <sub>2</sub> 30% (30) 2. FiO <sub>2</sub> 100% (30)	Orthopedic	No data	No	VC, TV 10 ml/kg ETco <sub>2</sub> 35–45 mmHg	0	2	1	2	0
Mackintosh <sup>61</sup>	1. FiO <sub>2</sub> 30% (25) 2. FiO <sub>2</sub> >90% (25) [3. FiO <sub>2</sub> 30% no PEEP (25)] [4. FiO <sub>2</sub> >90% no PEEP (25)]	Any elective surgery (open abdominal, airways, neuro excluded)	No data	No	TV 6–10 ml/kg ETco <sub>2</sub> 35–45 mmHg	0 or 3–5	2	2	1	2
Meyhoff <sup>63</sup>	1. FiO <sub>2</sub> 30% (701) 2. FiO <sub>2</sub> 80% (685)	Abdominal	Yes	No	Not standardized	No data	2	1	2	2
Myles <sup>64</sup>	1. FiO <sub>2</sub> 30% (1,015) 2. FiO <sub>2</sub> 80% (997)	Any >2 h; excluding cardiac or one-lung ventilation	Yes	No	Not standardized	No data	2	0	2	2
Staehr <sup>70</sup>	1. FiO <sub>2</sub> 30% (111) 2. FiO <sub>2</sub> 80% (102)	Laparotomy	Yes	Yes	Not standardized	No data	2	2	1	2
Staehr <sup>69</sup>	1. FiO <sub>2</sub> 30% (15) 2. FiO <sub>2</sub> 80% (20)	Gynecologic laparotomy	Yes	No	TV 8–10 ml/kg ETco <sub>2</sub> 4.5–6 kPa	5	2	2	1	2
Zoremba <sup>72</sup>	1. FiO <sub>2</sub> 40% (71) 2. FiO <sub>2</sub> 80% (71)	Minor peripheral	No data	Yes	TV 8 ml/kg ETco <sub>2</sub> 4–4.7 kPa	10	1	0	2	2

Quality assessment: R (randomization): 0 = none or pseudo-randomization, 1 = yes but not specified, 2 = yes and adequate; C (concealment of treatment allocation): 0 = none, 1 = yes; B (blinding): 0 = none, 1 = yes but not specified, 2 = yes and adequate; F (follow-up): 0 = none, 1 = reported but intention-to-treat analysis not possible, 2 = reported and intention-to-treat analysis possible. Trials are listed in alphabetical order. Staehr 2011 and 2012 are subgroup analyses of Meyhoff 2009.

BMI = body mass index; ETco<sub>2</sub> = end-tidal carbon dioxide; FiO<sub>2</sub> = inspired oxygen fraction; N<sub>2</sub>O = nitrous oxide; PEEP = positive end-expiratory pressure; TV = tidal volume; VC = volume-controlled ventilation.

another multicenter study reporting on SSI and pulmonary outcomes<sup>63</sup> were reported in two further articles; one concentrated on pulmonary outcomes in obese patients<sup>70</sup> and the other on pulmonary outcomes in patients scheduled for laparotomy for ovarian cancer.<sup>69</sup>

### Study Characteristics

Included reports were published between 2000 and 2012 (tables 1–3). The median quality score was 5.5 (range, 2–7). In experimental groups, intraoperative FiO<sub>2</sub> ranged from 80 to 100% (median, 80%), in controls ranged from 30 to 40% (median, 30%).


### Synthesis of Results

**Surgical Site Infection.** Nine studies (5,103 patients) reported on the incidence of SSI (table 1).<sup>4,5,28,30,58,62–64,66</sup> Six


studies considered SSI as an infection occurring within 14 days postoperatively, and two within 30 days;<sup>30,62</sup> one trial did not mention the duration of follow-up.<sup>28</sup> Seven studies used a standardized method for SSI assessment: three considered the ASEPSIS scoring system,<sup>4,5,58</sup> two used the definition of the Centers for Disease Control and Prevention,<sup>30,63</sup> and two considered a prospectively determined scoring system.<sup>28,66</sup> In all trials except one,<sup>30</sup> 90–100% of patients received prophylactic antibiotics.

Surgeries were colorectal, appendectomy, abdominal, and gynecologic. Two trials reported on abdominal and nonabdominal procedures.<sup>30,64</sup> The baseline risk of SSI, *i.e.*, the incidence of SSI in patients receiving normal FiO<sub>2</sub>, ranged from 7<sup>30</sup> to 27%.<sup>28</sup> When data were combined, there was an average incidence of 14.1% with normal FiO<sub>2</sub> and of 11.4% with high FiO<sub>2</sub>; RR, 0.77 (95% CI, 0.59–1.00; fig. 2A).

A



B



**Fig. 2.** (A) Impact of high oxygen fraction on surgical site infection. Included all surgeries. Surgeries were colorectal, appendectomy, abdominal, any except cardiac or one-lung, major abdominal, and gynecologic inclusive breast. (B) Impact of high oxygen fraction on surgical site infection. Included colorectal surgery only. On the Forrest plots, trials are listed in alphabetical order. On the event rate scatters, sizes of bubbles are proportional to sizes of trials. FIO<sub>2</sub> = inspired oxygen fraction.

Because data were heterogeneous ( $P_{hetero} = 0.03$ ), we used a random effects model.

Because it has been argued that patients undergoing colorectal surgery may particularly profit from a high FIO<sub>2</sub> regimen,<sup>24,26</sup> we performed a subgroup analysis including all patients undergoing colorectal surgery. Four trials were performed exclusively in patients undergoing colorectal surgery,<sup>4,5,28,62</sup> and from four, data from patients undergoing colorectal surgery could be extracted.<sup>30,63,64,66</sup> When all colorectal surgery data were combined (n = 1,977), there was an average incidence of SSI of 19.3% with normal FIO<sub>2</sub> and of 15.2% with high FIO<sub>2</sub>; RR, 0.78 (95% CI, 0.60–1.02; fig. 2B). The data were homogenous ( $P_{hetero} = 0.19$ ). We additionally performed a meta-analysis using a fixed effect model; the RR was 0.80 (95% CI, 0.66–0.97).


**PONV.** Eleven trials (2,293 patients) reported dichotomous data on presence or absence of nausea or vomiting (table 2).<sup>6,7,27,29,30,57,59,65,67,68,71</sup>

When combining all data, only prevention of late nausea showed statistical significance in favor of high FIO<sub>2</sub> (fig. 3A).

With normal FIO<sub>2</sub>, the average incidence of late nausea was 24.8%, with high FIO<sub>2</sub> was 19.5%; RR, 0.79 (95% CI, 0.66–0.93).

Because propofol and prophylactic antiemetics reduce the underlying risk of PONV, we performed a sensitivity analysis including exclusively data from patients who received an inhalational anesthetic without prophylactic antiemetics.<sup>6,7,27,29,57,59,67,68</sup> As expected, incidences of PONV outcomes in patients receiving normal FIO<sub>2</sub> were increased (fig. 3B). With normal FIO<sub>2</sub>, the average incidence of late nausea was 33.7%, with high FIO<sub>2</sub> was 29.3%; RR, 0.75 (95% CI, 0.62–0.90). With normal FIO<sub>2</sub>, the average incidence of late vomiting was 26.2%, with high FIO<sub>2</sub> was 19.2%; RR, 0.72 (95% CI, 0.56–0.92). When analyzing the composite endpoint, PONV, no statistical significance was reached.

**Pulmonary Outcomes.** Nine trials (3,698 patients) reported on pulmonary outcomes (table 3).<sup>55,56,60,61,63,64,69,70,72</sup> Six articles reported on atelectasis using chest radiographs and/or thoracic computed tomography scans for diagnosis (table 4); however, two of those<sup>69,70</sup> were subgroup analyses reporting



**Fig. 3.** (A) Impact of high oxygen fraction on postoperative nausea and vomiting. Showing summary of meta-analyses. (B) Impact of high oxygen fraction on postoperative nausea and vomiting. Inhalational anesthesia without antiemetic prophylaxis. Early = cumulative incidence to 6 h postoperatively;  $F_{IO_2}$  = inspired oxygen fraction; Late = cumulative incidence to 24 h postoperatively; PONV = postoperative nausea and vomiting (composite endpoint of any nausea and/or vomiting events). \*Random effects model; all others, fixed effect model.

on the same outcomes as the original larger study.<sup>63</sup> Thus, data from four trials, two small<sup>56,60</sup> and two large,<sup>63,64</sup> could be combined (fig. 4). The average incidence of atelectasis with high  $F_{IO_2}$  was 8.3%, with normal  $F_{IO_2}$  was 10.6%; RR, 0.93 (95% CI, 0.59–1.46).

Three small trials reported on perioperative blood gas analyses (table 4).<sup>55,60,69</sup> In one,<sup>55</sup> there was an evidence of statistically significant worsening of the intraoperative  $P_{aO_2}/F_{IO_2}$  ratio in patients receiving 100%  $F_{IO_2}$  (use of positive end-expiratory pressure and postoperative  $P_{aO_2}/F_{IO_2}$  ratio was not reported). The two other studies failed to show any detrimental effect on the postoperative  $P_{aO_2}/F_{IO_2}$  ratio with supplemental oxygen,<sup>60,69</sup> despite the use of 100% oxygen and no positive end-expiratory pressure in one trial.<sup>60</sup>

Three small studies reported on lung function (table 4).<sup>56,69,72</sup> In two studies, spirometry values were not different in patients receiving high or normal  $F_{IO_2}$ .<sup>56,69</sup> The third, including 142 moderately obese patients, reported on a variety of postoperative spirometric values that were

significantly worsened with high oxygen fraction.<sup>72</sup> Specifically, there was a linear decrease in postoperative lung function with increasing body mass index in the high-oxygen group.

Two studies reported on postoperative  $Sp_{O_2}$  values.<sup>69,72</sup> Both failed to show a significant decrease in the 24-h postoperative  $Sp_{O_2}$  in patients exposed to high  $F_{IO_2}$ .

Finally, one trial showed no difference in postoperative oxygen requirements among patients ventilated with a high or normal  $F_{IO_2}$ .<sup>61</sup>

## Discussion

We performed a systematic review and meta-analysis of clinical trials testing the role of high  $F_{IO_2}$  in patients undergoing surgery with general anesthesia. We studied outcomes that are relevant in this context, *i.e.*, SSI, PONV, and pulmonary complications. We analyzed data from 22 randomized trials (including 7,001 patients) that were reported in 26 articles.

When combining data of all eligible patients, regardless of the type of surgery, the risk of SSI decreased by 23% with high  $F_{IO_2}$  (RR, 0.77), and the difference was borderline statistically significant. When selecting patients undergoing colorectal surgery, the RR point estimate was similar, and depending on the statistical model that was used, the 95% CI included (random effects model) or excluded (fixed effect model) equality. Previous meta-analyses have yielded conflicting results on the potential benefit of high  $F_{IO_2}$  on SSI. Three reported on a significant reduction in the incidence of SSI.<sup>20,22,24</sup> A fourth analysis, similar to ours, reported on a statistically significant result in favor of high  $F_{IO_2}$  when a fixed effect model was used but failed to show any benefit with a random effects model.<sup>21</sup> Finally, a fifth analysis reported on a protective effect with high  $F_{IO_2}$  in patients undergoing colorectal surgery only, but not in patients undergoing other abdominal surgeries.<sup>26</sup> Many authors have considered that subgroup as the most likely to profit from a high  $F_{IO_2}$ .<sup>24,26</sup> The question then is, whether this benefit is of clinical relevance. Although the degree of antiinfective efficacy of high  $F_{IO_2}$  seems weak and perhaps disappointing, it seems to be similar to conventional antibiotic prophylaxis in many surgical settings.<sup>73</sup> In addition, as most patients in these trials had received prophylactic antibiotics, we may conclude on the efficacy of high  $F_{IO_2}$  as a supplemental antiinfection strategy only; the efficacy of high  $F_{IO_2}$  alone remains unclear and would be difficult to test from an ethical perspective because the administration of prophylactic antibiotics is widely considered as standard of care. In some trials, the incidence of SSI in controls was very low and in others it was more than 20%, despite prophylactic antibiotics. High  $F_{IO_2}$  appeared to be effective independent of the baseline risk of infection (fig. 2A).

The potentially beneficial effect of high  $F_{IO_2}$  on the incidence of PONV has been contentious, too. In 2007, an international consensus panel did not recommend supplemental oxygen for the prevention of PONV.<sup>74</sup> In 2008, two meta-analyses were addressing the potential benefit of high  $F_{IO_2}$  on PONV; one concluded that supplemental oxygen reduced the incidence of postoperative vomiting only<sup>25</sup> and the other was unable to identify any beneficial effect of high  $F_{IO_2}$ .<sup>23</sup> In our analysis, there was some evidence that high  $F_{IO_2}$  decreased the incidence of both nausea and vomiting in patients receiving an inhalational anesthetic and no prophylactic antiemetics. The baseline risk (*i.e.*, the incidence of PONV in controls) was increased in this context, and this may explain why high  $F_{IO_2}$  had more scope to show antiemetic efficacy. However, absolute risk reductions suggested that approximately 15 patients needed to receive high  $F_{IO_2}$  for one not to be nauseous or to vomit who would have done so had they received normal  $F_{IO_2}$ . This degree of prophylactic antiemetic efficacy is weak, as numbers-needed-to-treat of 3–5 (absolute risk reduction, 20–30%) may be expected

from an effective pharmacological antiemetic intervention in the surgical setting.<sup>74</sup> In addition, when analyzing the composite endpoint, PONV, no benefit was evident.

Nine trials reported on a large variety of pulmonary outcomes, including atelectasis, blood gases, lung spirometry, or postoperative  $Sp_{O_2}$ . Results were difficult to compare as outcome measures differed among studies. Dichotomous data on presence or absence of atelectasis could be combined from two small and two large trials. The result was clearly negative. Two studies reported on postoperative  $Pa_{O_2}/F_{IO_2}$  ratio. Both failed to show any detrimental effect of high  $F_{IO_2}$  on postoperative gas exchange, despite using ventilation settings known to acutely worsen pulmonary atelectasis<sup>11</sup> (*i.e.*, administration of 100%  $F_{IO_2}$  without positive end-expiratory pressure) in one trial. Additionally, in three studies reporting on surrogate outcomes, there was no evidence of pulmonary harm when using a high  $F_{IO_2}$  regimen. Only one trial, conducted in moderately obese patients, reported on a detrimental effect of high  $F_{IO_2}$  on spirometric values postoperatively.

Our aim was to combine data from well-controlled trials that had the scope to show beneficial or harmful effects of high  $F_{IO_2}$ , if there were any. Our study differs twofold from previously published similar meta-analyses.<sup>20–26</sup> First, none of the previously published meta-analyses attempted to provide a complete picture of the potentially beneficial (SSI and PONV) and harmful (pulmonary complications) effects of high  $F_{IO_2}$ . Second, our selection criteria were stricter. For instance, we excluded studies where oxygen was delivered *via* a facemask in awake patients with regional anesthesia,<sup>75–79</sup> or where supplemental oxygen was provided to patients in the postoperative period only.<sup>80–82</sup> Finally, to ensure that the trials had the scope of showing an effect with high  $F_{IO_2}$ , we arbitrarily defined that, for eligibility, the value of the normal  $F_{IO_2}$  had to be less than, or equal to, half of the high  $F_{IO_2}$  value.

Included trials were performed in patients undergoing different surgical procedure, with a variety of anesthetic regimens. Ideally, we would adjust these analyses for potential confounding factors; in practice, this was not feasible as the number of analyzed trials was limited. Critical analysis of all included trials suggested that they did not differ that much regarding potential confounders (tables 1–3). In addition, a certain degree of clinical heterogeneity ensures wide applicability, or external validity, of the results of these analyses. Because all trials were performed in adults only, the results may not be applicable to children. We did not include data from children,<sup>48–50</sup> as there is an argument, at least when testing the efficacy of an antiemetic intervention in the surgical setting, to distinguish between children and adults.<sup>83</sup> Also, because trials reporting on SSI included mainly patients undergoing abdominal surgery, extrapolation of our results to other types of surgery remains speculative. Concerning antibiotic prophylaxis, it has been argued that its efficacy in reducing the risk of wound infection may

**Table 4.** Impact of High Oxygen Fraction on Pulmonary Outcomes

First Author	Comparison			
	High $\text{FiO}_2$		Normal $\text{FiO}_2$	
	$\text{FiO}_2$ , %	Number of Patients	$\text{FiO}_2$ , %	Number of Patients
Postoperative atelectasis				
Akça <sup>56</sup>	80	16	30	14
Kotani <sup>60</sup>	100	30	30	30
Meyhoff <sup>63</sup>	80	685	30	701
Myles <sup>64</sup>	80	997	30	1,015
Staeher <sup>70*</sup>	80	102	30	111
Staeher <sup>69*</sup>	80	20	30	15
Perioperative blood gases				
Agarwal <sup>55</sup>	100	9	40	9
Kotani <sup>60</sup>	100	30	30	30
Staeher <sup>69*</sup>	80	20	30	15
Postoperative lung function				
Akça <sup>56</sup>	80	16	30	14
Staeher <sup>69*</sup>	80	20	30	15
Zoremba <sup>72</sup>	80	71	40	71
Postoperative $\text{SpO}_2$				
Staeher <sup>69*</sup>	80	20	30	15
Zoremba <sup>72</sup>	80	71	40	71
Postoperative $\text{O}_2$ requirement				
Mackintosh <sup>61</sup>	>90	50	30	50


\* Staeher 2011 and Staeher 2012 are subgroup analyses of Meyhoff 2009.

CT = computed tomography;  $\text{FEV}_1$  = forced expiratory volume in 1 s;  $\text{FiO}_2$  = inspired oxygen fraction; FVC = forced vital capacity; IQR = interquartile range;  $\text{O}_2$  = oxygen;  $\text{PaO}_2$  = arterial partial oxygen pressure;  $\text{SpO}_2$  = arterial oxygen saturation by pulse oximetry.

Table 4. (Continued)

Definition of Endpoint	Results	Statistical Significance, <i>P</i> Value
Comparison of pre- and postoperative chest radiograph by a physician unaware of patient's group assignment	High $F_{IO_2}$ : 44% Normal $F_{IO_2}$ : 36%	0.94
Postoperative CT scan obtained in all patients and evaluated by a physician unaware of patient's group assignment	High $F_{IO_2}$ : 94% Normal $F_{IO_2}$ : 64%	0.12
Comparison of pre- and postoperative chest radiograph by a physician unaware of patient's group assignment	High $F_{IO_2}$ : 23% Normal $F_{IO_2}$ : 17%	"Not significant" (no value reported)
Present if described in the radiologist's evaluation of chest radiograph or CT scan (not routinely prescribed in all patients)	High $F_{IO_2}$ : 7.9% Normal $F_{IO_2}$ : 7.1%	0.60
Present if described in chest radiograph or CT scan (not routinely prescribed for all patients)	High $F_{IO_2}$ : 7.5% Normal $F_{IO_2}$ : 13%	<0.001
All chest radiographs and CT were evaluated for infiltrate and atelectasis by the attending radiologist, who was blinded to allocation (not routinely prescribed for all patients)	High $F_{IO_2}$ : 8.8% Normal $F_{IO_2}$ : 6.3%	0.76
All chest radiographs and CT were evaluated for infiltrate and atelectasis by the attending radiologist, who was blinded to allocation (not routinely prescribed for all patients)	High $F_{IO_2}$ : 25% Normal $F_{IO_2}$ : 13%	0.51
Intraoperative $P_{aO_2}/F_{IO_2}$ ratio	High $F_{IO_2}$ : 351.5 (SD, 22.9) Normal $F_{IO_2}$ : 558 (SD, 46.6)	<0.0001
$P_{aO_2}/F_{IO_2}$ ratio 24 h postoperatively	High $F_{IO_2}$ : 389 (SD, 56) Normal $F_{IO_2}$ : 393 (SD, 49)	"Not significant" (no value reported)
$P_{aO_2}/F_{IO_2}$ ratio 90 min postoperatively (kPa)	High $F_{IO_2}$ : 50 (IQR, 42–57) Normal $F_{IO_2}$ : 56 (IQR, 37–60)	0.66
Spirometry ( $FEV_1$ , FVC, $FEV_1/FVC$ ratio)	A variety of lung function parameters with no significant difference between groups, 24 h postoperatively	
Spirometry (functional residual capacity), 2 h postoperatively (ml)	High $F_{IO_2}$ : 1,633 (IQR, 1,343–1,948) Normal $F_{IO_2}$ : 1,615 (IQR, 1,375–2,318)	0.70
Spirometry (mid-expiratory flow, FEV, forced inspiratory vital capacity)	A variety of lung function parameters "significantly" worse with high $F_{IO_2}$ compared with normal $F_{IO_2}$ at 0.5, 2, and 24 h	
$Sp_{O_2}$ <95%, 72 h postoperatively	High $F_{IO_2}$ : 35% Normal $F_{IO_2}$ : 13%	0.15
$Sp_{O_2}$ , 24 h postoperatively	High $F_{IO_2}$ : 97.5% (SD, 1.70) Normal $F_{IO_2}$ : 98% (SD, 2.0)	0.105
$O_2$ requirement to maintain $Sp_{O_2}$ >90%, 24 h postoperatively	High $F_{IO_2}$ : 0 l/min (IQR, 0–0) Normal $F_{IO_2}$ : 0 l/min (IQR, 0–0)	No statistically significant difference between groups

Study or Subgroup	High FIO <sub>2</sub>		Normal FIO <sub>2</sub>		Weight	Risk Ratio	
	Events	Total	Events	Total		M-H, Random, 95% CI	
Akça 1999 <sup>56</sup>	7	16	5	14	16.1%	1.23	[0.50, 3.00]
Kotani 2000 <sup>60</sup>	7	30	5	30	13.4%	1.40	[0.50, 3.92]
Meyhoff 2009 <sup>63</sup>	54	685	50	701	33.3%	1.11	[0.76, 1.60]
Myles 2007 <sup>64</sup>	75	997	127	1015	37.1%	0.60	[0.46, 0.79]
<b>Total (95% CI)</b>		<b>1728</b>		<b>1760</b>	<b>100.0%</b>	<b>0.93</b>	<b>[0.59, 1.46]</b>
Total events	143		187				
Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 9.16, df = 3 (P = 0.03); I <sup>2</sup> = 67%							
Test for overall effect: Z = 0.33 (P = 0.74)							



**Fig. 4.** Impact of high oxygen fraction on postoperative atelectasis. On the Forrest plot, trials are listed in alphabetical order. On the event rate scatter, sizes of *bubbles* are proportional to sizes of trials. F<sub>IO</sub><sub>2</sub> = inspired oxygen fraction.

be assumed for all types of surgery, even ones where no clinical trial data exist.<sup>73</sup>

In conclusion, intraoperative high F<sub>IO</sub><sub>2</sub> may be regarded as a supplemental strategy to further decrease the risk of SSI in patients receiving prophylactic antibiotics. Indirect comparison suggests that the degree of efficacy is similar to antibiotic prophylaxis in many surgical settings. However, the efficacy of high F<sub>IO</sub><sub>2</sub> *per se*, and in the absence of antibiotic prophylaxis, remains unknown. High F<sub>IO</sub><sub>2</sub> reduces the risk of PONV to some extent, although mainly in patients with inhalation anesthetics and without prophylactic antiemetics. Finally, intraoperative high F<sub>IO</sub><sub>2</sub> does not increase the risk of postoperative atelectasis.

The authors thank Pascal Thibon, M.D., M.Sc., Staff Infection Control Physician and Epidemiologist, Antenne, Régionale de Lutte contre les Infections Nosocomiales de Basse-Normandie, Centre Hospitalier Universitaire de Caen, Caen, France, who kindly responded to our inquiries.

## References

- Hopf HW, Holm J: Hyperoxia and infection. *Best Pract Res Clin Anaesthesiol* 2008; 22:553–69
- Kabon B, Kurz A: Optimal perioperative oxygen administration. *Curr Opin Anaesthesiol* 2006; 19:11–8
- Dellinger EP, Gross PA, Barrett TL, Krause PJ, Martone WJ, McGowan JE Jr, Sweet RL, Wenzel RP: Quality standard for antimicrobial prophylaxis in surgical procedures. *Infectious Diseases Society of America. Clin Infect Dis* 1994; 18:422–7
- Belda FJ, Aguilera L, García de la Asunción J, Alberti J, Vicente R, Ferrándiz L, Rodríguez R, Company R, Sessler DI, Aguilar G, Botello SG, Ortí R; Spanish Reduccion de la Tasa de Infeccion Quirurgica Group: Supplemental perioperative oxygen and the risk of surgical wound infection: A randomized controlled trial. *JAMA* 2005; 294:2035–42
- Greif R, Akça O, Horn EP, Kurz A, Sessler DI; Outcomes Research Group: Supplemental perioperative oxygen to reduce the incidence of surgical-wound infection. *N Engl J Med* 2000; 342:161–7
- Goll V, Akça O, Greif R, Freitag H, Arkiliç CF, Scheck T, Zoeggeler A, Kurz A, Krieger G, Lenhardt R, Sessler DI: Ondansetron is no more effective than supplemental intraoperative oxygen for prevention of postoperative nausea and vomiting. *Anesth Analg* 2001; 92:112–7
- Greif R, Laciny S, Rapf B, Hickie RS, Sessler DI: Supplemental oxygen reduces the incidence of postoperative nausea and vomiting. *ANESTHESIOLOGY* 1999; 91:1246–52
- Lumb AB: Just a little oxygen to breathe as you go off to sleep—Is it always a good idea? *Br J Anaesth* 2007; 99:769–71
- Rothen HU: Oxygen: Avoid too much of a good thing! *Eur J Anaesthesiol* 2010; 27:493–4
- Benoît Z, Wicky S, Fischer JF, Frascarolo P, Chapuis C, Spahn DR, Magnusson L: The effect of increased FIO<sub>2</sub> before tracheal extubation on postoperative atelectasis. *Anesth Analg* 2002; 95:1777–81
- Duggan M, Kavanagh BP: Pulmonary atelectasis: A pathogenic perioperative entity. *ANESTHESIOLOGY* 2005; 102:838–54
- Edmark L, Kostova-Aherdan K, Enlund M, Hedenstierna G: Optimal oxygen concentration during induction of general anesthesia. *ANESTHESIOLOGY* 2003; 98:28–3
- Loeckinger A, Kleinsasser A, Keller C, Schaefer A, Kolbitsch C, Lindner KH, Benzer A: Administration of oxygen before tracheal extubation worsens gas exchange after general anesthesia in a pig model. *Anesth Analg* 2002; 95:1772–6
- Broex EC, van Asselt AD, Bruggeman CA, van Tiel FH: Surgical site infections: How high are the costs? *J Hosp Infect* 2009; 72:193–1
- de Lissovoy G, Fraeman K, Hutchins V, Murphy D, Song D, Vaughn BB: Surgical site infection: Incidence and impact on hospital utilization and treatment costs. *Am J Infect Control* 2009; 37:387–97
- Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR: Guideline for prevention of surgical site infection, 1999. *Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol* 1999; 20:250–78; quiz 279–80
- Lachaine J: Therapeutic options for the prevention and treatment of postoperative nausea and vomiting: A pharmacoeconomic review. *Pharmacoeconomics* 2006; 24:955–70
- Kranke P, Eberhart LH: Possibilities and limitations in the pharmacological management of postoperative nausea and vomiting. *Eur J Anaesthesiol* 2011; 28:758–65
- Parra-Sanchez I, Abdallah R, You J, Fu AZ, Grady M, Cummings K III, Apfel C, Sessler DI: A time-motion economic analysis of postoperative nausea and vomiting in ambulatory surgery. *Can J Anaesth* 2012; 59:366–75
- Al-Niामी A, Safdar N: Supplemental perioperative oxygen for reducing surgical site infection: A meta-analysis. *J Eval Clin Pract* 2009; 15:360–5
- Brar MS, Brar SS, Dixon E: Perioperative supplemental oxygen in colorectal patients: A meta-analysis. *J Surg Res* 2011; 166:227–35

22. Chura JC, Boyd A, Argenta PA: Surgical site infections and supplemental perioperative oxygen in colorectal surgery patients: A systematic review. *Surg Infect (Larchmt)* 2007; 8:455–61
23. Orhan-Sungur M, Kranke P, Sessler D, Apfel CC: Does supplemental oxygen reduce postoperative nausea and vomiting? A meta-analysis of randomized controlled trials. *Anesth Analg* 2008; 106:1733–8
24. Qadan M, Akça O, Mahid SS, Hornung CA, Polk HC Jr: Perioperative supplemental oxygen therapy and surgical site infection: A meta-analysis of randomized controlled trials. *Arch Surg* 2009; 144:359–66; discussion 366–7
25. Rincón DA, Valero JF: [Supplemental oxygen for the prevention of postoperative nausea and vomiting: A meta-analysis of randomized clinical trials]. *Rev Esp Anesthesiol Reanim* 2008; 55:101–9
26. Togioka B, Galvagno S, Sumida S, Murphy J, Ouanes JP, Wu C: The role of perioperative high inspired oxygen therapy in reducing surgical site infection: A meta-analysis. *Anesth Analg* 2012; 114:334–42
27. McKeen DM, Arellano R, O'Connell C: Supplemental oxygen does not prevent postoperative nausea and vomiting after gynecological laparoscopy. *Can J Anaesth* 2009; 56:651–7
28. Schietroma M, Carlei F, Cecilia EM, Piccione F, Bianchi Z, Amicucci G: Colorectal Infraperitoneal anastomosis: The effects of perioperative supplemental oxygen administration on the anastomotic dehiscence. *J Gastrointest Surg* 2012; 16:427–34
29. Šimurina T, Mraović B, Mikulandra S, Sonicki Z, Sulen N, Dukić B, Gan TJ: Effects of high intraoperative inspired oxygen on postoperative nausea and vomiting in gynecologic laparoscopic surgery. *J Clin Anesth* 2010; 22:492–8
30. Thibon P, Borgey F, Boutreux S, Hanouz JL, Le Coutour X, Parienti JJ: Effect of perioperative oxygen supplementation on 30-day surgical site infection rate in abdominal, gynecologic, and breast surgery: The ISO2 randomized controlled trial. *ANESTHESIOLOGY* 2012; 117:504–11
31. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *BMJ* 2009; 339:b2535
32. Elia N, Tramèr MR: Ketamine and postoperative pain—A quantitative systematic review of randomised trials. *Pain* 2005; 113:61–70
33. Fakhry SM, Montgomery SC: Peri-operative oxygen and the risk of surgical infection. *Surg Infect (Larchmt)* 2012; 13:228–33
34. Lumb AB, Nair S: Effects of increased inspired oxygen concentration on tissue oxygenation: Theoretical considerations. *Eur J Anaesthesiol* 2010; 27:275–9
35. Fleischmann E, Lenhardt R, Kurz A, Herbst F, Fülesdi B, Greif R, Sessler DI, Akça O; Outcomes Research Group: Nitrous oxide and risk of surgical wound infection: A randomised trial. *Lancet* 2005; 366:1101–7
36. Tramèr M, Moore A, McQuay H: Omitting nitrous oxide in general anaesthesia: Meta-analysis of intraoperative awareness and postoperative emesis in randomized controlled trials. *Br J Anaesth* 1996; 76:186–93
37. Tramèr MR: A rational approach to the control of postoperative nausea and vomiting: Evidence from systematic reviews. Part I. Efficacy and harm of antiemetic interventions, and methodological issues. *Acta Anaesthesiol Scand* 2001; 45:4–13
38. Karabayirh S, Alver F, Alkis N: Comparison of the supplemental oxygen, dexametasone and ondansetron for prevention of postoperative nausea and vomiting. *Turk Anesteziyoloji ve Reanimasyon* 2003; 31:110–5
39. Pizov R, Weiss YG, Oppenheim-Eden A, Glickman H, Goodman S, Koganov Y, Barak V, Merin G, Kramer MR: High oxygen concentration exacerbates cardiopulmonary bypass-induced lung injury. *J Cardiothorac Vasc Anesth* 2000; 14:519–23
40. Sinha PK, Neema PK, Unnikrishnan KP, Varma PK, Jaykumar K, Rathod RC: Effect of lung ventilation with 50% oxygen in air or nitrous oxide *versus* 100% oxygen on oxygenation index after cardiopulmonary bypass. *J Cardiothorac Vasc Anesth* 2006; 20:136–42
41. Smith CE, Maille JG, Tousignant G: Effects of inspired oxygen tension on hemodynamics and pulmonary gas exchange in patients undergoing coronary artery surgery. *J Cardiothorac Anesth* 1988; 2:633–42
42. Anthony T, Murray BW, Sum-Ping JT, Lenkovsky F, Vornik VD, Parker BJ, McFarlin JE, Hartless K, Huerta S: Evaluating an evidence-based bundle for preventing surgical site infection: A randomized trial. *Arch Surg* 2011; 146:263–9
43. Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I, Zernak C, Danner K, Jokela R, Pocock SJ, Trenkler S, Kredel M, Biedler A, Sessler DI, Roewer N; IMPACT Investigators: A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. *N Engl J Med* 2004; 350:2441–51
44. Joyce CJ, Baker AB: Effects of inspired gas composition during anaesthesia for abdominal hysterectomy on postoperative lung volumes. *Br J Anaesth* 1995; 75:417–21
45. Joyce CJ, Baker AB, Chartres S: Influence of inspired nitrogen concentration during anaesthesia for coronary artery bypass grafting on postoperative atelectasis. *Br J Anaesth* 1995; 75:422–7
46. Reber A, Budmiger B, Wenk M, Haefeli WE, Wolff T, Bein T, Skarvan K: Inspired oxygen fraction after cardiopulmonary bypass: Effects on pulmonary function with regard to endo-thelin-1 concentrations and venous admixture. *Br J Anaesth* 2000; 84:565–70
47. Reber A, Engberg G, Wegenius G, Hedenstierna G: Lung aeration. The effect of pre-oxygenation and hyperoxygenation during total intravenous anaesthesia. *Anaesthesia* 1996; 51:733–7
48. Donaldson AB: The effect of supplemental oxygen on postoperative nausea and vomiting in children undergoing dental work. *Anaesth Intensive Care* 2005; 33:744–8
49. Treschan TA, Zimmer C, Nass C, Stegen B, Esser J, Peters J: Inspired oxygen fraction of 0.8 does not attenuate postoperative nausea and vomiting after strabismus surgery. *ANESTHESIOLOGY* 2005; 103:6–10
50. von Ungern-Sternberg BS, Regli A, Schibler A, Hammer J, Frei FJ, Erb TO: The impact of positive end-expiratory pressure on functional residual capacity and ventilation homogeneity impairment in anesthetized children exposed to high levels of inspired oxygen. *Anesth Analg* 2007; 104:1364–8
51. Lentschener C, Benhamou D: Effect of intra-operative mechanical ventilation using 50% inspired oxygen on pulmonary oxygenation. *Eur J Anaesthesiol* 1997; 14:385–8
52. Purhonen S, Niskanen M, Wüstefeld M, Mustonen P, Hynynen M: Supplemental oxygen for prevention of nausea and vomiting after breast surgery. *Br J Anaesth* 2003; 91:284–7
53. Toraman F, Evrenkaya S, Senay S, Karabulut H, Alhan C: Adjusting oxygen fraction to avoid hyperoxemia during cardiopulmonary bypass. *Asian Cardiovasc Thorac Ann* 2007; 15:303–6
54. Sadrolsadat SH, Shoroghi M, Farahbakhsh F, Moharreri RS, Sheikhhvatan M, Abbasi A: The effect of supplemental 70% oxygen on postoperative nausea and vomiting in patients undergoing inguinal hernia surgery. *Hernia* 2008; 12:167–71
55. Agarwal A, Singh PK, Dhiraj S, Pandey CM, Singh U: Oxygen in air (FiO2 0.4) improves gas exchange in young healthy patients during general anesthesia. *Can J Anaesth* 2002; 49:1040–3
56. Akça O, Podolsky A, Eisenhuber E, Panzer O, Hetz H, Lampl K, Lackner FX, Wittmann K, Grabenwoeger F, Kurz A, Schultz AM, Negishi C, Sessler DI: Comparable postoperative pulmonary atelectasis in patients given 30% or 80% oxygen during and 2 hours after colon resection. *ANESTHESIOLOGY* 1999; 91:991–8

57. Bhatnagar S, Mishra S, Gupta M, Singhal AK, Mandal AS: Effects of different concentrations of intraoperative supplemental oxygen on post-operative nausea and vomiting (PONV) in patients under going modified radical mastectomy. *Inter J Anesthesiol* 2005; 9:12
58. Bickel A, Gurevits M, Vamos R, Ivry S, Eitan A: Perioperative hyperoxygenation and wound site infection following surgery for acute appendicitis: A randomized, prospective, controlled trial. *Arch Surg* 2011; 146:464–70
59. Joris JL, Poth NJ, Djamadar AM, Sessler DI, Hamoir EE, Defêchereux TR, Meurisse MR, Lamy ML: Supplemental oxygen does not reduce postoperative nausea and vomiting after thyroidectomy. *Br J Anaesth* 2003; 91:857–61
60. Kotani N, Hashimoto H, Sessler DI, Muraoka M, Hashiba E, Kubota T, Matsuki A: Supplemental intraoperative oxygen augments antimicrobial and proinflammatory responses of alveolar macrophages. *ANESTHESIOLOGY* 2000; 93:15–25
61. Mackintosh N, Gertsch MC, Hopf HW, Pace NL, White J, Morris R, Morrissey C, Wilding V, Herway S: High intraoperative inspired oxygen does not increase postoperative supplemental oxygen requirements. *ANESTHESIOLOGY* 2012; 117:271–9
62. Mayzler O, Weksler N, Domchik S, Klein M, Mizrahi S, Gurman GM: Does supplemental perioperative oxygen administration reduce the incidence of wound infection in elective colorectal surgery? *Minerva Anesthesiol* 2005; 71:21–5
63. Meyhoff CS, Wetterslev J, Jorgensen LN, Henneberg SW, Høgdall C, Lundvall L, Svendsen PE, Møllerup H, Lunn TH, Simonsen I, Martinsen KR, Pulawska T, Bundgaard L, Bugge L, Hansen EG, Riber C, Gocht-Jensen P, Walker LR, Bendtsen A, Johansson G, Skovgaard N, Heltø K, Poukinski A, Korshin A, Walli A, Bulut M, Carlsson PS, Rodt SA, Lundbeck LB, Rask H, Buch N, Perdawid SK, Reza J, Jensen KV, Carlsen CG, Jensen FS, Rasmussen LS; PROXI Trial Group: Effect of high perioperative oxygen fraction on surgical site infection and pulmonary complications after abdominal surgery: The PROXI randomized clinical trial. *JAMA* 2009; 302:1543–50
64. Myles PS, Leslie K, Chan MT, Forbes A, Paech MJ, Peyton P, Silbert BS, Pascoe E; ENIGMA Trial Group: Avoidance of nitrous oxide for patients undergoing major surgery: A randomized controlled trial. *ANESTHESIOLOGY* 2007; 107: 221–31
65. Piper SN, Röhm KD, Boldt J, Faust KL, Maleck WH, Kranke P, Suttner SW: Inspired oxygen fraction of 0.8 compared with 0.4 does not further reduce postoperative nausea and vomiting in dolasetron-treated patients undergoing laparoscopic cholecystectomy. *Br J Anaesth* 2006; 97:647–53
66. Pryor KO, Fahey TJ III, Lien CA, Goldstein PA: Surgical site infection and the routine use of perioperative hyperoxia in a general surgical population: A randomized controlled trial. *JAMA* 2004; 291:79–7
67. Purhonen S, Niskanen M, Wüstefeld M, Hirvonen E, Hynynen M: Supplemental 80% oxygen does not attenuate post-operative nausea and vomiting after breast surgery. *Acta Anaesthesiol Scand* 2006; 50:26–31
68. Purhonen S, Turunen M, Ruohoaho UM, Niskanen M, Hynynen M: Supplemental oxygen does not reduce the incidence of postoperative nausea and vomiting after ambulatory gynecologic laparoscopy. *Anesth Analg* 2003; 96:91–6
69. Staehr AK, Meyhoff CS, Henneberg SW, Christensen PL, Rasmussen LS: Influence of perioperative oxygen fraction on pulmonary function after abdominal surgery: A randomized controlled trial. *BMC Res Notes* 2012; 5:383
70. Staehr AK, Meyhoff CS, Rasmussen LS; PROXI Trial Group: Inspiratory oxygen fraction and postoperative complications in obese patients: A subgroup analysis of the PROXI trial. *ANESTHESIOLOGY* 2011; 114:1313–9
71. Turan A, Apfel CC, Kumpch M, Danzeisen O, Eberhart LH, Forst H, Heringhaus C, Isselhorst C, Trenkler S, Trick M, Vedder I, Kerger H: Does the efficacy of supplemental oxygen for the prevention of postoperative nausea and vomiting depend on the measured outcome, observational period or site of surgery? *Anaesthesia* 2006; 61:628–33
72. Zoremba M, Dette F, Hunecke T, Braunecker S, Wulf H: The influence of perioperative oxygen concentration on postoperative lung function in moderately obese adults. *Eur J Anaesthesiol* 2010; 27:501–7
73. Bowater RJ, Stirling SA, Lilford RJ: Is antibiotic prophylaxis in surgery a generally effective intervention? Testing a generic hypothesis over a set of meta-analyses. *Ann Surg* 2009; 249:551–6
74. Gan TJ, Meyer TA, Apfel CC, Chung F, Davis PJ, Habib AS, Hooper VD, Kovac AL, Kranke P, Myles P, Philip BK, Samsa G, Sessler DI, Temo J, Tramèr MR, Vander Kolk C, Watcha M; Society for Ambulatory Anesthesia: Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. *Anesth Analg* 2007; 105:1615–28
75. Gardella C, Goltra LB, Laschansky E, Drolette L, Magaret A, Chadwick HS, Eschenbach D: High-concentration supplemental perioperative oxygen to reduce the incidence of postcesarean surgical site infection: A randomized controlled trial. *Obstet Gynecol* 2008; 112:545–52
76. Khaw KS, Wang CC, Ngan Kee WD, Pang CP, Rogers MS: Effects of high inspired oxygen fraction during elective caesarean section under spinal anaesthesia on maternal and fetal oxygenation and lipid peroxidation. *Br J Anaesth* 2002; 88:18–23
77. Khaw KS, Wang CC, Ngan Kee WD, Tam WH, Ng FF, Critchley LA, Rogers MS: Supplementary oxygen for emergency Caesarean section under regional anaesthesia. *Br J Anaesth* 2009; 102:90–6
78. Pécora FS, Malbouisson LM, Torres ML: [Supplemental oxygen and the incidence of perioperative nausea and vomiting in cesarean sections under subarachnoid block]. *Rev Bras Anesthesiol* 2009; 59:558–69
79. Phillips TW Jr, Broussard DM, Sumrall WD III, Hart SR: Intraoperative oxygen administration does not reduce the incidence or severity of nausea or vomiting associated with neuraxial anesthesia for cesarean delivery. *Anesth Analg* 2007; 105:1113–7
80. Ghods AA, Soleimani M, Narimani M: Effect of postoperative supplemental oxygen on nausea and vomiting after cesarean birth. *J Perianesth Nurs* 2005; 20:200–5
81. Scifres CM, Leighton BL, Fogertey PJ, Macones GA, Stamilio DM: Supplemental oxygen for the prevention of postcesarean infectious morbidity: A randomized controlled trial. *Am J Obstet Gynecol* 2011; 205:267.e1–9
82. Turtiainen J, Saimanen EI, Partio TJ, Mäkinen KT, Reinikainen MT, Virkkunen JJ, Vuorio KS, Hakala T: Supplemental postoperative oxygen in the prevention of surgical wound infection after lower limb vascular surgery: A randomized controlled trial. *World J Surg* 2011; 35:1387–95
83. Eberhart LH, Geldner G, Kranke P, Morin AM, Schäuffelen A, Treiber H, Wulf H: The development and validation of a risk score to predict the probability of postoperative vomiting in pediatric patients. *Anesth Analg* 2004; 99:1630–7